Kassem Sameer, Samuels Noah, Gressel Orit, Stein Nili, Golan Miri, Ben-Arye Eran
Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3436212, Israel.
Department of Medicine, Carmel Medical Center, Clalit Health Services, Haifa 3436212, Israel.
J Clin Med. 2025 Mar 7;14(6):1800. doi: 10.3390/jcm14061800.
Research on quality of life (QoL)-related concerns among patients with both diabetes mellitus (DM) and cancer is limited. This study compared the QoL-related concerns and characteristics among chemotherapy-treated patients with cancer and DM to those without DM. Chemotherapy-treated patients were evaluated during integrative oncology (IO) consultations, which included evidence-based complementary therapies recommended by their healthcare providers to address quality of life (QoL) concerns. During these consultations, the participants were assessed for comorbidities, including diabetes mellitus (DM). QoL-related concerns were measured using the Edmonton Symptom Assessment Scale (ESAS) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Of the 1171 patients referred for an IO consultation, 272 (23.2%) had an established diagnosis of DM. The DM patients were older, presented with more advanced stages of cancer, and had more chronic comorbidities ( < 0.001). While fatigue was the most frequently reported QoL-related concern in both groups, the patients with DM had more severe pain scores in the ESAS (4.9 vs. 4.4, = 0.022) and lower ESAS well-being scores (5.9 vs. 5.5, = 0.021). Chemotherapy-treated patients with cancer and DM are characterized by higher rates of comorbidities and report more severe scores for pain and for poorer general well-being. Oncologists and diabetologists should consider referring patients with both diagnoses for an IO consultation to address their QoL-related concerns. More research is needed to understand the impact of IO consultations and treatments on well-being among patients diagnosed with both DM and cancer.
对同时患有糖尿病（DM）和癌症的患者中与生活质量（QoL）相关问题的研究有限。本研究比较了接受化疗的癌症合并糖尿病患者与无糖尿病患者在QoL相关问题及特征方面的差异。在综合肿瘤学（IO）会诊期间对接受化疗的患者进行评估，会诊内容包括医疗服务提供者推荐的基于证据的补充疗法，以解决生活质量（QoL）问题。在这些会诊期间，对参与者的合并症进行评估，包括糖尿病（DM）。使用埃德蒙顿症状评估量表（ESAS）和欧洲癌症研究与治疗组织生活质量问卷（EORTC QLQ-C30）来测量与QoL相关的问题。在1171名被转诊进行IO会诊的患者中，272名（23.2%）已确诊患有DM。糖尿病患者年龄更大，癌症分期更晚，且有更多慢性合并症（P<0.001）。虽然疲劳是两组中最常报告的与QoL相关的问题，但糖尿病患者在ESAS中的疼痛评分更高（4.9对4.4，P = 0.022），ESAS幸福感评分更低（5.9对5.5，P = 0.021）。接受化疗的癌症合并糖尿病患者的特点是合并症发生率更高，疼痛评分更严重，总体幸福感更差。肿瘤学家和糖尿病学家应考虑将两种疾病都有的患者转诊进行IO会诊，以解决他们与QoL相关的问题。需要更多的研究来了解IO会诊和治疗对同时诊断为DM和癌症的患者幸福感的影响。
